NortonHealthcare, Inc.
Louisville, Kentucky 40207
3 studies enrolling now · 18 studies all time
What they study most
Advanced Solid Tumor, Blood Cancer, Breast Cancer, Carcinoma, Non-Small-Cell Lung, DDR Gene Mutation, Diffuse Large B Cell Lymphoma, GBM, Gastric Cancer, Hematological Malignancy, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Acute, Lumbar Spinal Stenosis
Studies at this site
- MILD® Percutaneous Image-Guided Lumbar Decompression: A Medicare Claims Study — Recruiting now
- Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma — Recruiting now
- Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63) — Recruiting now
- Zimmer Biomet Shoulder Arthroplasty PMCF — Recruiting now
- GEN1046 Safety Trial in Patients With Malignant Solid Tumors — Running, not enrolling
- A Study Comparing Venetoclax and Azacitidine Plus Cusatuzumab to Venetoclax and Azacitidine in Newly Diagnosed AML Ineligible for Intensive Therapy — Running, not enrolling
- Study of LP-184 in Patients With Advanced Solid Tumors — Running, not enrolling
- A Study of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy in Patients With HER2-Positive Breast Cancer Who Have Residual Tumor in the Breast or Axillary Lymph Nodes Following Preoperative Therapy (KATHERINE) — Completed
- Orathecin + Gemcitabine Versus Placebo + Gemcitabine in Chemonaive Non-Resectable Pancreatic Cancer — Stopped early
- Safety, PD & Efficacy of MT-3724 for the Treatment of Patients With Relapsed or Refractory DLBCL — Stopped early
- A Study With Neoadjuvant mFOLFOX7 Plus Cetuximab to Determine the Surgical Conversion Rate for Unresectable Colorectal Cancer With Metastases Confined to the Liver — Completed
- Concordance of Inivata Liquid Biopsy With Standard of Care Tissue Testing — Completed
- OSI-774 (Tarceva) Plus Gemcitabine in Patients With Locally Advanced, Unresectable or Metastatic Pancreatic Cancer. — Completed
- A Study of Trastuzumab Emtansine Versus Taxane in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric Cancer — Stopped early
- A Study of the Experimental Drug BKM120 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Activation — Completed
- A Study of Erlotinib (Tarceva) After Surgery With or Without Adjuvant Chemotherapy in Non-Small Cell Lung Carcinoma (NSCLC) Patients Who Have Epidermal Growth Factor Receptor (EGFR) Positive Tumors — Completed
- Erlotinib (Tarceva) as a Single Agent or Intercalated With Combination Chemotherapy in Patients With EGFR Positive NSCLC — Completed
- Erlotinib vs. Standard Chemotherapy in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) and Eastern Cooperative Oncology Group (ECOG)Performance Status (PS) 2 — Completed